// App-Quantinova.ai

MON-299 : KIDNEY OUTCOMES ASSOCIATED WITH INITIATION OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITION VERSUS OTHER GLUCOSE LOWERING DRUGS - AN ANALYSIS FROM THE CVD-REAL STUDY

Researchers

Presenter

  • H. Lambers Heerspink

Principal Investigators

  • M. Thuresson

  • P. Fenici

  • A. Kasarik

  • M. Kosiborod

Medical Centers

  • Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Department of Cardiovascular Diseases, Kansas City, USA

  • University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, Netherlands

  • Statisticon AB, Biostatistics, Uppsala, Sweden

  • AstraZeneca, Global Medical Affairs, Cambridge, United Kingdom

  • Institute of Endocrinology, Tel Aviv University and Maccabi Healthcare Israel, Tel Aviv, Israel

Locations

  • United States

  • Netherlands

  • Sweden

  • United Kingdom

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Microvascular complications of diabetes 1

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved